# Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL

> **NCT05093140** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 30 (estimated)

## Conditions studied

- Primary Extranodal Lymphoma
- DLBCL

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT05093140
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2023-06
- **Final completion:** 2024-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05093140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05093140, "Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05093140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*